



ANNUAL REPORT & ACCOUNTS

2021

CONTENTS

- 03 Vision / Mission / Values
- 04 Chairman's Introduction
- 05 Income & Spend
- 06 2021 in Numbers
- 07 Research
- 12 Information
- 14 Awareness
- 16 Support
- 20 Our Fundraising Approach
- 22 Thank You
- 23 Reference and Administrative Details
- 24 Report of The Trustees
- 29 Report of the Independent Auditors
and Financial Statements



OUR VISION

A WORLD WHERE PRIMARY BONE CANCER IS CURED

OUR MISSION

TO SAVE LIVES AND IMPROVE OUTCOMES FOR PEOPLE AFFECTED BY PRIMARY BONE CANCER

OUR VALUES

- **PIONEERING** WE LEAD THE WAY, WE LEAVE NO STONE UNTURNED, WE ARE PREPARED TO TAKE RISKS.
- **DYNAMIC** WE DON'T STAND STILL, WE INNOVATE, WE CELEBRATE EVERY SUCCESS.
- **SUPPORTIVE** WE LISTEN, WE UNDERSTAND, WE CARE.
- **KNOWLEDGEABLE** WE KNOW OUR STUFF, WE ARE EAGER TO KNOW MORE.
- **TRUSTWORTHY** WE DO WHAT WE SAY.

CHAIRMAN'S INTRODUCTION

Welcome to our 2021 Annual Report & Accounts, an extra special report that not only summarises our annual performance but the performance of our 15th anniversary year.

2021 was yet another year where the primary bone cancer community stood by our side and allowed us to do more than ever before. We passed new records as a charity, which would be brilliant in any year, but these were ever more extraordinary in the wake of the COVID-19 pandemic.

We started 2021 determined to return our activities to pre-pandemic levels. Our ambition was to invest over £1million into new pioneering research projects. And, thanks to the continued record-breaking success of our fundraising, we were able to do just that – we spent over £1.4million on research, far more than ever before. Since 2006, we have now awarded over £5million in research grant funding. We also generated new levels of interest in primary bone cancer research, with record numbers of funding enquiries and applications being received.

Our awareness work reached new audiences and we continued our Awareness Initiative for a second year, focussing efforts on continued GP training and education of Dental Healthcare Professionals. Our campaigning drove record levels of individuals accessing our website information pages and in total, our messaging was seen over 57 million times across the UK. Our work was even externally recognised, receiving the first prize Advocacy in Action Award from SPEAN (Sarcoma Patients EuroNet).

Throughout the year we continued to see increasing pressures and challenges hitting our patients and their families, exacerbated by the impact of the COVID-19 pandemic. Our Support & Information Service continued to adapt to the emerging needs of our community, holding 68 online virtual events, introducing face to face events again and re-introducing the Bone Cancer Conference in virtual form. In all, our service had over 1,600 contacts with patients and their families, our highest ever usage.

Enabling all our work was you, our community of incredible supporters. You took on new levels of personal challenge and gave your time and funds to ensure that our life-saving work could continue and maintain pace. The record-breaking levels of fundraising we were able to achieve has ensured that our planned work and activities into next year and beyond can go ahead. I am always inspired by the selfless drive and determination of our wonderful community, and we cannot thank you enough for your continued efforts.

Looking to the future, we asked you for your views on what our priorities and focus should be. We listened to your feedback and started planning the future activities of our charity beyond our current strategic period ending in 2022. I am delighted to say these plans will be launched in October 2022, as part of Bone Cancer Awareness Week.

In preparing for the future, it is essential that we are correctly structured and equipped to maintain our trajectory of change. In recognition of our new needs, scope and scale, we appointed a new Chief Executive Officer in November, Mat Cottle-Shaw. Mat will spearhead our efforts and lead our incredible Staff Team to achieve our future ambitions. He will also ensure the needs of our patients and community are put at the heart of all we do.

I am so proud of where we are today as a charity. As an organisation that relies almost entirely on public donations to continue our vital work, I feel a new sense of hope whenever we fund a new research project, complete an awareness campaign, or support another patient when they need it most – and it is all thanks to you! Whilst ever we have your continued support, we will be here... Until there's a cure.




Andy Lewis
Chairman




INCOME & SPEND



Our income in 2021 totalled **£4,673,023**. This came from:



Our total expenditure in 2021 was: **£2,828,865**



A CLOSER LOOK AT OUR CHARITABLE SPEND



FOR EVERY £1
WE SPENT ON FUNDRAISING
£8.20 WAS RAISED
FOR OUR LIFE-SAVING WORK

During 2021 a further £2,620,000 (not included in the charts above) was committed to planned research and awareness campaigns due to take place from 2022 onwards.

THIS TAKES THE AMOUNT THAT WE HAVE COMMITTED TO CHARITABLE ACTIVITIES IN 2021 TO £4,865,838

2021 IN NUMBERS

57,655,490		Our awareness and campaigning activities were seen 57,655,490 times
5,714,000		2,857 individuals completed 5,714,000 burpees as part of their fundraising
4,673,023		We raised a record-breaking £4,673,023 for our vital work
3,985,749		561,909 individuals accessed 3,985,749 pages on our website
3,500,000		Bone Cancer Awareness Week reached over 3.5 million individuals across the UK
1,490,936		We spent £1,490,936 on research – more than ever before!
1,488,570		1,488,570 miles were cycled, ran, or walked in support of our work
318,340		Our patient stories were accessed 318,340 times as a source of information and support
246,662		Our dedicated information pages were accessed 210,405 times
208,729		Our social media followers grew to 208,729 from around the world
147,641		147,641 donations were received from 68,731 amazing people
74,796		Our symptoms information page was accessed 74,796 times
13,000		Over 13,000 individuals took on challenges and proactively fundraised to support our life-saving work
14,491		Our information resources were downloaded 14,491 times
6,013		6,013 individuals signed up to collect stamps as part of our Stamp Appeal
5,154		5,154 education materials were downloaded as part of our Bone Cancer Awareness Initiative
1,600		Our Support & Information Service made over 1,600 contacts
1,100		1,100 individuals had joined our 9 digital support groups
1,080		Our Step-By-Step Guide for Patients was downloaded 1,080 times
126		We awarded 126 Financial Assistance Grants to patients
99		We reached 99 research grants being awarded since 2006
96		Up to 96% of primary bone cancer patients are now being approached to donate tissue samples for use in research.
68		We held 68 in-person and virtual support events
6		Because of the support of our community, we awarded 6 extra research projects
2		We held 2 research symposiums
1		1 incredible community made all of this possible – our supporters.

RESEARCH



In line with our strategy, **The Biggest Ever Commitment To Primary Bone Cancer**, in July 2017 we launched our new 2017 – 2022 Grant Programme. The below table demonstrates the progress of this programme to date:

2017-2022 Grant Programme

GRANT TYPE/YEAR	2017	2018	2019	2020	2021	2022
CLINICAL / TRANSLATIONAL		✓			✓	
EARLY CAREER FELLOWSHIP						✓
PHD STUDENTSHIP		✓✓		✓	✓	
INFRASTRUCTURE GRANTS	✓✓ ✓✓	✓✓✓ ✓✓	✓✓✓ ✓✓	✓✓✓ ✓✓	✓✓✓ ✓✓	
EXPLORER	✓✓	✓	✓✓	✓	✓✓✓	✓
IDEAS	✓✓	✓	✓✓	✓✓✓	✓✓✓	✓
LARGE RESEARCH PROJECT					✓✓	
OTHER RESEARCH INVESTMENT	✓	✓	✓	✓	✓	✓

✓ AWARDED AS PLANNED ✓ ADDITIONAL UNPLANNED AWARD ✓ CALL CANCELLED DUE TO ADDITIONAL PHD STUDENTSHIP ✓ PLANNED ✓ GRANT AWARD DEFERRED TO 2021
 ✓ GRANT AWARD DEFERRED TO 2021 DUE TO COVID-19 DISRUPTION ✓ GRANT AWARD DEFERRED TO 2022 DUE TO COVID-19 DISRUPTION

RESEARCH

New Grants awarded in 2021

LEAD RESEARCHER	PROJECT TITLE	GRANT TYPE	AWARD VALUE
Professor Adrienne Flanagan	Sample Collection Support Grant - Stanmore (Y4)	Infrastructure	£28,396
Mr Jonathan Stevenson	Sample Collection Support Grant - Birmingham (Y4)	Infrastructure	£29,897
Mr Kenneth Rankin	Sample Collection Support Grant - Newcastle (Y4)	Infrastructure	£16,000
Dr Sandra Strauss	ICONIC: Improving outcome through Collaboration in Osteosarcoma (Stage 2)	Clinical Translational	£175,000
Professor Aykut Uren	2nd Generation Clofarabine derivatives as CD99 inhibitors	Explorer	£70,000
Professor Gareth Veal	Optimising the Treatment of Teenagers and Young Adults with Ewing Sarcoma through an Increased Understanding of Clinical Pharmacology and Toxicity Biomarkers	Explorer	£145,530
Professor Susan Burchill	International collaboration to optimise the management of patients with Ewing sarcoma	Explorer	£149,622
Dr Darrell Green	TP53 restoration using mRNA vaccine technology	Ideas	£20,000
Dr Karan Shah	Delineating the role of hypoxic extracellular vesicles in pulmonary metastasis of osteosarcoma – a pilot study	Ideas	£19,867
Dr Kogularamanan Suntharalingam	Bone-seeking metal-based drugs to overcome chemotherapy-resistant osteosarcoma sub-populations	Ideas	£20,000
Professor Sibylle Mitnacht	Developing genome-informed treatment to improve outcome in Osteosarcoma	Large Research Project	£249,204
Dr Olivier Pardo	Modulation of interferon gamma-mediated signalling and immune response by fibroblast growth factor 2 in osteosarcoma	Large Research Project	£249,781
Dr Martin Pule	Towards Engineered T Cells for Osteosarcoma (Year 1 Award)	PhD Studentship	£34,614

Projects receiving additional funding to continue progress

LEAD RESEARCHER	PROJECT TITLE	GRANT TYPE	AWARD VALUE
Professor Robert Falconer	Development of a targeted methotrexate prodrug with enhanced therapeutic index for osteosarcoma	PhD Studentship	£16,626
Professor Alison Gartland	The Role of Oestrogen in Chondrosarcoma Using Patient-Derived Xenograft Mouse Models: A Pilot study	Ideas	£16,667

Collaborative projects supported by Bone Cancer Research Trust

LEAD RESEARCHER	PROJECT TITLE	AWARDED TO	AWARD VALUE
Dr Sandra Strauss	Improving outcome in Sarcoma through Analysis and interrogation of National Cancer Data	Sarcoma UK	£43,082
Dr Sandra Strauss	Euro Ewing Consortium	University College London	£36,091



RESEARCH



2021 saw laboratories return to normal working practices following the COVID-19 pandemic. This allowed our Grant Programme to get back on track and, for the first time in our history, we awarded over £1million in research grants to 13 projects. We also received accreditation for best practice as a medical and healthcare research charity by the Association of Medical Research Charities (AMRC) and our Infrastructure Grants were highlighted by AMRC in their impact report as best practice for collaborative research.

As part of our 15th anniversary celebrations, we opened a unique grant call, allowing researchers to apply for funding for projects of all levels. This was our largest ever grant call and proved to be a tremendous success with 25 applications being received. Throughout the year, we received 40 applications for funding - more than ever before. This upward trend is an excellent sign that our reputation continues to grow as the leading source of funding for primary bone cancer research. It also indicates more attention and priority is being paid to primary bone cancer research and we are determined to explore all possible ways to ensure the maximum amount of research can be funded for our patients.

In response to the strength of applications we received, we were delighted to award 6 extra unplanned grants through the year. This included 2 Ideas Grant, 1 Explorer Grant, 2 Large Research Project Grants and an additional PhD Studentship. These awards marked several new milestones for our charity, being our 10th awarded PhD Studentship to date and our first ever international research grant being awarded to Professor Aykut Üren at Georgetown University in Washington DC.

In all, we awarded 13 grants in 2021, all focused on driving forward the development of new treatments for patients, supporting essential infrastructure to support wider primary bone cancer research, increasing our understanding of the disease and ensuring current essential projects can continue. A further two awards were also granted to existing researchers to continue their promising research and expand further on their progress made to date.

During the year we opened applications for our first ever Early Career Fellowship. This is a key award of our 2017 - 2022 Grant Programme as it represents our largest ever grant designed to support an upcoming researcher develop their own programme of research in primary bone cancer. We also launched The Hamilton Osteosarcoma Research Programme, a dedicated and unexpected £1million research programme dedicated to the development of osteosarcoma treatments. Both of these exciting projects will be awarded in 2022.

As part of our research strategy, we are committed to facilitating and generating collaboration wherever possible. Highlights of the year included our second International Ewing Sarcoma Research Symposium and our second Osteosarcoma Symposium. The meetings were incredibly successful, attracting international attendance and generating new ideas and areas of interest for potential future research.

Following each meeting we have continued to work closely with individuals, this has resulted in new research groups and applications being formed.

At the heart of all our research are our patients. It is essential that their views and lived experiences of primary bone cancer inform and shape the research we fund. To embed this principle further, we developed and launched our Patient & Public Involvement Panel (PPIP). By the end of the year, we were pleased to have recruited over 17 volunteers to form part of this new panel. Each member bringing a personal and unique perspective of primary bone cancer. The panel will support researchers in the development of their research applications and provide invaluable feedback and insight to the research community that would otherwise be missing.

“ Being involved in PPIP has meant that I can use my knowledge and experience, as well as improve my understanding of osteosarcoma, to help source beneficial research in the treatment of this devastating disease. I feel I'm doing something positive to instigate change that will help other families directly.

Jenny Wick, PPIP member and parent of a patient.

In addition to the creation of our PPIP, in 2021 we wanted to expand the international representation on our Independent Scientific Advisor Panel (ISAP). Through the year we were delighted to welcome three new members: Professor Thomas Grünwald, Dr Nathalie Gaspar and Dr Didier Surdez. Together they add representation and knowledge from Germany, France and Switzerland. We thank all our ISAP members for their invaluable support and dedication to the progression of primary bone cancer research.

Further milestones during the year also included our first ever award to support consortia. We were delighted to partner with the Ewing's Sarcoma Research Trust to fund the EURO EWING Consortium, a group that remains pivotal to the development of future international clinical trials and collaborative research in Ewing sarcoma. ICONIC, our first ever funded clinical trial, surpassed recruitment of 100 osteosarcoma patients. During the year we awarded the second phase funding of the ICONIC project which continues to be the only project of its kind for osteosarcoma patients of all ages in the UK.

2017-2022

WHAT WE SAID WE'D DO & WHAT WE DID...

We will commit over £2.8 million to pioneering research through an innovative new grant programme.

Our total investment into pioneering research in 2021 was £1,490,936 which includes the award of 13 new research grants, second phase funding to 2 existing projects and supporting 2 collaborative projects.

We will support research at all levels, from initial idea through to clinical trial.

2021 saw us fund 3 Ideas projects focusing on innovative new treatments for osteosarcoma and chordoma, 2 Explorer projects focusing on Ewing sarcoma research and the second phase of the clinical trial ICONIC.

We will deliver the next generation of world class, primary bone cancer researchers.

During 2021 we were delighted to award our 10th PhD Studentship, bringing another talented individual into the field of primary bone cancer. We also, for the first time, awarded funding to senior post-doctoral researchers to aid their career progression in primary bone cancer research.

We will continue to support UK surgical centres to enable all primary bone cancer patients to contribute tissue samples for use in research.

In 2021 we were pleased to re-award Infrastructure Grants to 3 of the 5 bone cancer surgical centres in England. Two centres did not require additional funding due to awards in 2020 still remaining post-pandemic.

WHAT WE'RE GOING TO DO IN 2022...

- 01 We will launch a new and ambitious Research Strategy.
- 02 We will proactively support researchers through the expansion of our Patient & Public Involvement Panel, encouraging researchers to use this invaluable resource whenever possible.
- 03 We will award our first programme grant, supporting collaborative research in osteosarcoma to improve patient outcomes.
- 04 We will award our first ever Early Career Fellowship.
- 05 We will expand our existing Grant Programme to include new grant types, including Consortia and Skills Development Grants.
- 06 We will promote Skills Development Grants to improve knowledge and skill gaps in the primary bone cancer research community and to promote our research being shared at national and international conferences.
- 07 We will continue to explore collaborations that will bring greater benefit to our patients.
- 08 We will hold face to face symposia focused on multiple primary bone cancers.



INFORMATION



2021 continued to be an unusual year for our information provision. With the effects of the COVID-19 pandemic still being felt by many patients and their families, we continued to focus our efforts online to ensure even those in the most remote situations could access information when and how they needed it. We saw a 17% increase in use of our online information pages compared to 2020 with pages being accessed 246,662 times.

To support individuals of varied ages and experiences, we held online events and webinars throughout the year. These events were dedicated to specific topics, including fear of recurrence, body image, dealing with diagnosis as a younger person and long-term survival – to name a few.

“ The Bone Cancer Research Trust have helped me understand more about my loved one’s diagnosis; talk through worries and access other organisations who may be able to help us.

The wife of a current patient

A key highlight was the development of our new video resources dedicated to helping those who may be facing or have had an amputation. We worked with focus groups to ensure the videos would be as effective as possible. This resulted in 9 videos being produced, each focusing on different aspects. Each video was delivered by former patients and healthcare professionals with lived experiences of primary bone cancer. The videos were made available online in November and had been watched 1,587 times by the end of December, we continue to receive positive feedback about them and are exploring potentially similar videos in the future.


At the Bone Cancer Research Trust, we continue to be the only organisation offering dedicated information covering all forms of primary bone cancer and tumour. The below chart demonstrates the usage of this information by tumour type:

During the year we started to review our all our information. We launched newly revised online webpages mid-year and expanded our information to also provide a dedicated page on the symptoms of primary bone cancer, this page was accessed 74,796 times in 2021 – our highest ever accessed information page.

We continued to make available and distribute our factsheets to patients, healthcare professionals and all those involved in a primary bone cancer journey. In all, 2,868 were distributed and a further 1,675 guidance pages on specific bone cancer surgical centres were also shared.

“ They have accurate information on what I need. I feel I can ask as many questions as I need to.

A healthcare professional



22071 Spindle Cell Sarcoma of the Bone

12297 Ewing sarcoma

13062 Chondrosarcoma

10491 Giant Cell Tumour of the Bone

7919 Angiosarcoma of the Bone

6499 Ameloblastoma

3113 Osteosarcoma

3285 Adamantinoma

1831 Chordoma

2017-2022

WHAT WE SAID WE'D DO & WHAT WE DID...

We will develop a Patient / Parent Pack to offer comprehensive information to all patients on their specific primary bone cancer or tumour type.

We continued to promote our highly successful Step-By-Step Guide for Patients. This invaluable resource was accessed over 3,500 times throughout the year.

We will expand our existing portfolio of information for patients of all ages.

Our new amputation resources are aimed at patients of all ages and have been developed as a series of short videos to make these easily digestible.

Our dedicated Children's resources continued to see popular demand for those seeking to help educate and support younger patients, Harry has an Operation was downloaded 798 times and Abbie has Osteosarcoma was downloaded 636 times.

We will expand our basic information to ensure patients in other countries have access to relevant information.

Our information was shared with Sarcoma Patients EuroNet (SPAEN) to allow access by patients across Europe. Our symptoms information was translated to several different languages, including Spanish, French and Italian.

Our social media campaigns continued to promote our information throughout the UK and overseas. Our website pages were accessed over 2.5million times throughout the year from individuals in overseas countries. Top accessing countries included the United States, Germany, Russia, Canada and India.

We will ensure that information is available for the clinical and medical community.

Our dedicated hub for healthcare professionals was accessed 1106 times and continued to provide invaluable tailored and dedicated information covering all aspects of primary bone cancer.

We will develop information for carers and families of patients with primary bone cancer.

Through our Support and Information Service we continued to provide direct information and support to carers and family members of patients through our Support & Information Line and our online and offline events.

We will accurately signpost relevant information that falls outside our remit.

Our signposting hub was accessed over 886 times throughout the year, taking individuals to organisations that can offer help and serviced beyond our remit.

WHAT WE'RE GOING TO DO IN 2022...

- 01** We will optimise our online information pages to improve accessibility and will begin work developing a new website.
- 02** We will update and re-launch our Ewing sarcoma and osteosarcoma information booklets.
- 03** We will add to our online information pages to include greater detail on statistics and incidence.
- 04** We will apply for Patient Information Forum (PIF) accreditation, ensuring we meet best practice in patient information production.
- 05** We will re-introduce Information Days at bone cancer surgical centres.



STRATEGIC OBJECTIVES & ACHIEVEMENTS

AWARENESS



2021 was a record year for our public reach at the Bone Cancer Research Trust. Our campaigning activities were seen over 57 million times - a year on year increase of 73%. In addition to educating the public, we continued our efforts to educate healthcare professionals, circulating over 71,280 training resources.

We started the year with a real highlight, receiving the first prize Advocacy in Action Award from SPEAN (Sarcoma Patients EuroNet) for the first phase of our Bone Cancer Awareness Initiative, which was completed in 2020. For Bone Cancer Awareness Week 2021 we launched the second phase of the project, this time focused on the training of dental healthcare professionals. Like GPs, dental healthcare professionals receive little-to-no training on how to spot red flag symptoms of primary bone cancer, despite 14% of cases being in the skull, face and jaw. For the campaign, we were delighted to team up with Portman Dental Care and launch a UK-wide campaign where we held online training webinars and sent education packs to 11,370 dental practices and 18 dental schools. In total, our campaign was seen 3.5million times and featured in regional broadcast media.

In February, we were delighted to collaborate with Sarcoma UK to launch a medical student survey. This crucial data helped us to understand the specific educational needs within this target group and gave rise to an ongoing joint project between our two charities. In May, we launched our joint Sarcoma Awareness Project for junior doctors and awarded seven fellowships, allowing junior doctors to undertake a placement at a sarcoma centre and learn more about how the disease is managed. The purpose of the project is to educate medical professionals earlier in their career and equip them with a greater understanding of primary bone cancer / bone sarcomas.

During Sarcoma Awareness Month in July, we launched a new report called 15 Years of Research – Working Towards a Cure. This inspiring piece was showcased at our 15th Anniversary Party, where examples of our work were displayed for our supporters to read. The event was a celebration like no other in our history, blending celebration with fundraising and it introduced our inaugural Bone Idol Awards. These unique and special awards recognised individuals from across the whole primary bone cancer community, from fundraisers and volunteers to researchers and surgeons. In all, 12 awards were presented on the night to outstanding individuals who really do represent the very best of our community. The awards generated media interest across the UK and brought many healthcare professionals into direct contact with our life-saving work for the first time.

To understand the current picture with primary bone cancer incidence, survival, and diagnosis, we had planned to complete an independent analysis of data held by Public Health England in 2021. However, as a charity we always strive to collaborate wherever possible and try to avoid duplication of efforts with life-minded organisations. Therefore, we were pleased to combine efforts with Sarcoma UK again and begin plans for funding a joint project in this area. We are expecting this work to start in 2022.

2021
THE BONE IDOLS

CONGRATULATIONS
TO ALL OUR 2021 BONE IDOLS:

Dr Phillip Green, Professor Pam Kearns, Helen Buglass, Julie Wantling, Karen Schurer, Lee Morris, Louise & Mike Ashton, Jeremy Reynolds, Pete Lloyd, Professor Lee Jeys, Dr Sandra Strauss and Sue & Andy Collard.

2017-2022

WHAT WE SAID WE'D DO & WHAT WE DID...

We will ensure all GPs in the UK have access to the training and tools they need to identify and diagnose primary bone cancer.

Throughout 2021 we continued to promote materials from our 2020 Bone Cancer Awareness Initiative campaign. These were accessed 6,913 times during the year and our education webinars were seen 1,904 times.

We will develop tools to allow radiographers, physiotherapists, and other medical professionals to identify the symptoms of primary bone cancer.

Our wider healthcare professional materials were distributed 638 times during the year and our Bone Cancer Awareness Week campaign focused on the training of Dentists on primary bone cancers of the head and neck. In total, 71,280 training resources were sent to 11,370 dental practices across the UK.

We will continue to fund and develop training options for medical students in the field of primary bone cancer.

We continued to provide information and materials to medical schools throughout the UK and we welcomed 4 students from The University of Sheffield, supporting them on projects specifically related to primary bone cancer.

We collaborated with Sarcoma UK to understand the training needs of medical students and funded the National Sarcoma Awareness Project, aimed at educating medical students and junior doctors on sarcomas.

We will increase national and, where possible, international public awareness of primary bone cancer and the Bone Cancer Research Trust.

We continued to build momentum through our campaigning activity which was seen 57,655,490 times during the year.

WHAT WE'RE GOING TO DO IN 2022...

- 01 We will work collaboratively to fund a data analyst to capture key primary bone cancer statistics, including incidence, survival, and routes & time to diagnosis. This will inform our work on early diagnosis.
- 02 We will support training fellowships for medical students and junior doctors to work in a sarcoma specialist centres to gain valuable and career lasting knowledge in sarcoma.
- 03 We will present at the British Sarcoma Group meeting; highlighting the issues that our patients face with delayed diagnosis.
- 04 We will formalise and expand our Healthcare Expert Panel and develop a strategic plan to improve the awareness of primary bone cancer amongst the public and healthcare professionals.
- 05 We will launch a new 10-year strategy as part of Bone Cancer Awareness Week.

SUPPORT



As the primary bone cancer community continued to navigate the COVID-19 pandemic, we also continued to react and adjust our approach to support as many people as we could. Our Support & Information Service made over 1,600 contacts with patients, family members and carers throughout the year and delivered 68 in-person and virtual support events. We also awarded £8,520 to assist patients with the financial pressures that come with a primary bone cancer diagnosis, through our Financial Assistance Grants.

For a long time, it has been known that the additional financial pressures of a cancer diagnosis can cause added distress for patients and their families. To help alleviate some of these pressures, we launched our Financial Assistance Grants on February 4th; World Cancer Day. By the end of 2021 we had awarded 141 of these grants which have been incredibly well received by patients.

“ Thanks to everyone at the Bone Cancer Research Trust for being able to offer our patients some financial support. The patients are really grateful for it.

A healthcare professional

Throughout the year we continued to hold our weekly 'Virtual Cuppa'. This event has become a key aspect of our service and is regularly attended by up to 12 individuals affected by primary bone cancer. Additionally, we held tailored virtual events for younger individuals – focusing on a positive activity as a way to engage with others and share experiences. We also continued to work with Henry Dancer Days, providing Virtual Storytime to children in need of a positive escape from the reality of primary bone cancer.

“ I want to say thank you for the Virtual Cuppas this year. The way you've presented them has been fantastic.

Former patient

As part of Bone Cancer Awareness Week, we held our flagship support event, the Bone Cancer Conference. Due to the ongoing impact of the COVID-19 pandemic, it was not possible to hold the event face to face, so we took the event online with a theme of 'Reuniting our community'. For the first time ever, delegates were able to join from around the world and watch back sessions multiple times. 22 guest speakers covered subjects from prosthetics to surgery to clinical trials.

“ Thank you and thank you for all the support you give us. It's going to be vital over the next few months and it's a huge help knowing where to find it without going looking.

Parent of a current patient

To help patients and carers navigate specific topics, we continued to hold virtual webinars. These have proven to be really successful and are being planned for 2022.

“ “The Fear of Recurrence webinar was really good. We've had and will soon have a number of Teenage Young Adults finishing treatment so it's been a really helpful watch.

Teenage Cancer Trust Youth Support Co-Ordinator

We know that lived experiences of primary bone cancer are an essential source of information and support for new patients. We continued to promote our Virtual Support groups throughout the year which now have well over 1,100 members sharing their experiences. We also continued to promote the sharing of personal stories. Throughout the year our patient stories were viewed 318,340 times, this is an increase of 130% compared to 2020.



2017-2022

WHAT WE SAID WE'D DO & WHAT WE DID...

We will provide a listening ear service that allows current patients or family members to talk with someone that has been through a similar experience.

Our Support & Information Service made over 1,600 contacts throughout the year.

We will develop digital 'community' support groups.

Our 9 Digital Support Groups continue to attract new patients, family members and carers to provide a safe environment for shared lived experiences and to ask questions.

We will deliver an annual conference aimed at uniting and supporting our community.

The Bone Cancer Conference returned virtually in October and was attended by 52 individuals.

We will actively promote the sharing of patient stories and experiences.

25 new patient stories were developed and shared through 2021 and our Support & Information Service proactively brought together families and individuals with similar experiences to gain mutual support.

We will ensure robust signposting to other support groups and charities where we cannot provide assistance.

Our Support & Information Team now actively signpost to 87 organisations across the UK offering help and support beyond our remit, such as counselling, legal advice, and practical assistance with matters such as travel insurance.

WHAT WE'RE GOING TO DO IN 2022...

- 01 We will hold two Bone Cancer Conferences at venues across the UK.
- 02 We will commence face-to-face support meetings across the UK, enabling patients to gain peer-to-peer support.
- 03 We will expand our Support & Information Service to include WhatsApp messaging, increasing our accessibility for patients.
- 04 We will expand our collaboration with Henry Dancer Days to offer personalised 1-to-1 storytelling sessions for children affected by primary bone cancer.
- 05 We will develop specific support for bereaved parents and families and for siblings of patients.



OUR SUPPORT & INFORMATION SERVICE

For anyone in need of information or support with any aspect of coping with or dealing with primary bone cancer – we're here.

The approach of our service is to be dynamic and patient-led; we aim to provide our community with an added layer of support on top of that provided by healthcare professionals, who we work hand-in-hand with.

Our service provides:

- A freephone Support & Information Line - 0800 111 4855 (Mon - Fri 9am - 5pm)
- Financial assistance grants for every new patient in the UK
- Virtual primary bone cancer & tumour support groups across the UK
- Confidential and professional support from our dedicated team
- Access to reliable, accurate and award-winning bone cancer and tumour specific information
- An annual conference, bringing together our community in a supportive and safe environment
- A library of Support & Information Webinars, covering topics pertinent to primary bone cancer
- Dedicated digital community support groups
- Correct signposting to organisations that can provide greater assistance
- Access to patient stories and the opportunity to be connected with others, who have had similar experiences



OUR FUNDRAISING APPROACH

In 2021, 147,641 donations were made to support our life-saving work from 68,731 amazing people. Over 13,000 incredible individuals undertook a challenge or activity, from running to skydiving to going orange for the day – all to help bone cancer patients. We thank every single one of our supporters; because of them we raised a record breaking £4,673,023 to help primary bone cancer patients.

At the Bone Cancer Research Trust, we take a relationship-first approach to all our fundraising activities, seeking to build meaningful and long-term relationships with all our supporters. We strive to ensure that anyone choosing to support our charity has the best possible experience and we continually learn from and review our activities to shape our approach in the future.

During the year, we continued to offer online and offline fundraising opportunities. Our virtual fundraising challenges continued to be a successful source of significant income and our dedicated efforts were recognised in November as we won the Best Virtual Fundraising Event Award from Fundraising Everywhere. Our offline campaigns continued to engage existing supporters of our charity and we were lucky enough to secure our second BBC Radio 4 Appeal in December, which generated over £17,000.

Our continued drive to diversify our income and reduce reliance on any one income stream has allowed us to grow and significantly refine our fundraising approach. We have seen significant success in our community-based fundraising which has continued to go from strength to strength. 2021 was another year where we attracted new proactive and ongoing volunteer fundraisers to lead our Special Funds. We continue to provide personal and ongoing support, guidance, and materials to facilitate their tireless efforts.

In April, we received our first ever donation of £1million. This incredibly generous personal donation will fund The Hamilton Programme of Osteosarcoma Research, an entirely new research programme of research dedicated to driving forward new treatments for osteosarcoma. This will be awarded in 2022.

In all our activities we aim to ensure that our supporters and the wider public are treated fairly and with respect. We continually monitor and review our practices to ensure we are adhering to the latest in fundraising regulations and practices. The Bone Cancer Research Trust also voluntarily subscribes to the Fundraising Regulator and its Code of Fundraising Practice. All staff are aware of and adhere to Charity Commission guidelines and The Code of Fundraising Practice which sets out statutory obligations and best practice standards.

Whilst our fundraising activities have grown in recent years, we do not employ third party fundraising organisations to work on our behalf or use methods of fundraising that can be seen as intrusive or persistent. We are also very conscientious about self-regulation of our fundraising activities and protecting vulnerable people. We are especially careful and sensitive when engaging with those affected by cancer.

The Bone Cancer Research Trust continued to be a member of the Fundraising Regulator. During 2021 we received no complaints from the regulator relating to any of our fundraising activities.





THANK YOU

The Bone Cancer Research Trust relies almost entirely on public support to continue our life-saving work — whether this be through financial donations, fundraising, donating time, or donating skills and services. We would like to thank every single person who has supported us in 2021 – without you, we could not do what we do for primary bone cancer patients!

Special Funds

We would like to thank all our Special Funds and their supporters for their unwavering support and dedication...

Abigail's Ambition, Adam Dealey, Adam Hassall Tribute Fund, Adam Panther Tribute Fund, Alexander Albiston Tribute Fund, Al Dawson Tribute Fund, Alex Lewis Memorial Fund, Anthony Pilcher Bone Cancer Trust, Ashton's Fund, Campaigns for Caroline, Chloë's Fight, Chris Fairley Fund, Christopher Spratt Tribute Fund, Daniel Bridle Memorial Fund, Daniel Humphreys Tribute Fund, The Darren Wilkinson Amelo Warrior Fund, Dila's Fund, Emily Barker Tribute Fund, Fitzzy's Fund, Flora's Fund, For the Love of Stephen, Frank's Fund, Freddie's Future, Gemma Pickering Tribute Fund, Guy Francis Tribute Fund, The Jack Sparrow Fund, James Stewart Tribute Fund, Jennifer Carvell Tribute Fund, Jessica Gower My Blue Heart Fund, Jordon Wilson Tribute Fund, Josh Williamson Tribute Fund, Jude's Fund, Kenny McCabe Tribute Fund, Ken Davies Tribute Fund, Kieran's Legacy, Krystle Smith Tribute Fund, Laura Connolly Tribute Fund, Liberty's Legacy, Liz Clarke-Saul Fund, Lol's Legacy, Mary Collard Tribute Fund, Matt's Beacon Fund, Menafest, Nick Pollard Tribute Fund, Pushing for a Cure, Rhodri Jones Memorial Appeal, Ruth Grace's Battle, Sam's Fund, The Scott Abbruzzese Memorial Fund, Tom Stead Tribute Fund, Zack Foley Fund

Our Active Ambassadors

Laurence Whiteley, Peter Lloyd, Dr Phillip Green, Charlene Young

Corporates, Trusts and Foundations

Albert Gubay Charitable Foundation
Balcombe Trust
Barbour Foundation
Clive Richards Foundation
David Brooke Charity
Department for Business, Energy & Industrial Strategy
Ewing's Sarcoma Research Trust
February Foundation
Garfield Weston Foundation
Michael Davie Research Foundation
Miss Margaret Butters Reekie Charitable Trust
P F Charitable Trust
Robert Luff Foundation Ltd

Volunteers

Adam Bowers, Aimee Hunter, Benjamin Lang, Brenda Peel, Felicity Smith, Johnny Quinn, Julie Scorer, Terri Bush

...as well as all the many individuals who have supported us at fundraising events and are taking part in our Stamp Appeal.

Information Review Panel

Dr Darrell Green, Dr Elizabeth Roundhill, Dr Katrina Ingley, Dr Lucia Cottone, Dr Phil Green, Dr Sandra Strauss, Geraint Davies, Millicent Lipshaw, Mr Kenneth Rankin, Mr Muzzammil Nusrath, Pete Lloyd, Professor Bernadette Brennan, Professor Paul Cool

REFERENCE AND ADMINISTRATIVE DETAILS FOR YEAR ENDED 31ST DECEMBER 2021

Trustees:

Andrew Lewis (Chair until 30/4/2022)
Alison Gartland (Chair from 30/4/2022)
Roger Paul
Gillian Elizabeth Johnston
Sarah Bernadette Dawson (retired 19/1/22)
Malcom Matthews (retired 5/4/21)
Damien Harper
James Maffin
Bernadette Brennan
Arlene Eves
Darrell Green
Jonathan Stevenson
Elizabeth Eatock (appointed 23/10/21)

Clerk to the Trustees:

Elizabeth Eatock (resigned 30/4/22)
Jenny Connolley (appointed 30/4/22)

Independent Scientific Advisory Panel:

Chair: Professor Pam Kearns

MBChB, BSc (Hons), PhD, FRCPCH, Professor of Clinical Paediatric Oncology and Honorary Consultant in Paediatric Oncology, University of Birmingham

Deputy Chair: Professor Robert Brown

Chair in Translational Oncology, Imperial College London and The Institute of Cancer Research

Lay Member: Dr Phil Green

Lay member of Independent Scientific Advisory Panel

Member: Piers Gaunt

BSc MSc, Senior Biostatistician, University of Birmingham

Member: Dr Paulo Ribeiro

BSc MSc PhD, Senior Lecturer and Group Leader, Bart's Cancer Institute

Member: Professor Thomas Grünwald

MD, Division Head, Translational Paediatric Sarcoma Research, German Cancer Research Center, Heidelberg, Germany

Member: Dr Nathalie Gaspar

Paediatric Oncologist, Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, France

Member: Dr Didier Surdez

Senior Researcher in the lab of Olivier Delattre, Institut Curie, Paris

Principal Address

Unit 10, Feast Field
Horsforth, Leeds, LS18 4TJ

Registered Charity Number

1159590

Senior Management Team

Mr M Cottle Shaw – CEO
Mrs Z Davison – Head of research and information
Mrs C Taylor – Head of finance
Mrs L Riach – Head of fundraising and communications (appointed 22/3/22)

Independent Auditors

Thomas Coombs Limited
Statutory Auditor, Chartered Accountants
3365 The Pentagon, Century Way
Thorpe Park, Leeds
West Yorkshire, LS15 8ZB

Bankers

CAF Bank Ltd
25 Kings Hill Avenue, Kings Hill
West Malling, ME19 4JQ

Lloyds Bank
65-68 Briggate, Leeds
West Yorkshire, LS1 6LH

Solicitors

Shakespeare Martineau
Waterfront House
35 Station Street
Nottingham
NG2 3DQ

HR Consultants

The HR Dept Ltd
First Floor
3 Brook Office Park
Emersons Green
Bristol
BS16 7FL

Investment Managers

Brewin Dolphin
10 Wellington Place
Leeds, LS1 4LX

REPORT OF THE TRUSTEES FOR YEAR ENDED 31ST DECEMBER 2021

The trustees present their report with the financial statements of the charity for the year ended 31st December 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives And Activities

Objectives and Aims

The Bone Cancer Research Trust (BCRT) became a Charitable Incorporated Organisation (CIO) on 1st January 2015 and is a trust that is governed by a Trust Deed and managed by a Board of Trustees. The Constitution states that the object of the CIO is the relief of sickness generally and in particular, but not so as to limit the generality of the foregoing:

- i) promoting research into the causes and treatment of primary bone cancer and publishing useful results thereof; and**
- ii) providing support and information services for persons suffering from primary bone cancer and their treatment.**

Our vision is a world where primary bone cancer is cured. Our mission is to save lives and improve outcomes for people affected by primary bone cancer by being:

- The catalyst for pioneering research
- The trusted source of information
- The voice of the primary bone cancer community
- A supportive network for the people affected.

The trustees have complied with the duty set out in Section 4 of the Charities Act 2011 and have paid due regard to the public benefit guidance published by the Charity Commission.

Board Of Trustees

Andy Lewis - Chair

Andy has 40 years' experience in technology, project management and consultancy. He has worked as a Founding Board Member (BBC Technology), a Company Director and a Programme Director (NCR, BBC, Siemens, ITV, Coopers and Lybrand, Sainsburys, RBS). Andy's son, Alex, passed away from Osteosarcoma in February 2011.

Roger Paul - Deputy Chair

Roger's business life was in telecommunications, working in an executive position with AT&T. His daughter, Claudia, died at the age of 17, following a three-year battle with Ewing sarcoma. Her final wish was for Roger to help children in her position in the future, and consequently, he has been a trustee for 10 years.

Bernadette Brennan

Bernadette is a Professor in Paediatric Oncology and Consultant Paediatric Oncologist at Royal Manchester Children's Hospital and The Christie NHS Foundation Trust.

She is a NCRI Sarcoma Chair and member of the YOSS, Bone and STS subgroup, she chairs the CCLG (Childhood Cancer and Leukaemia Group) Rare Tumour Group and is a member of EXPeRT European Rare Tumour Group. She has given a number of invited lectures for learned societies and research groups both in the UK and overseas.

Sarah Dawson

Sarah is a Coach and HR Training Consultant who became a trustee after her son Al died in November 2007. Sarah lectures on related topics and spreads awareness of primary bone cancer to a wide range of audiences including students in nursing and other allied healthcare professionals.

Arlene Eves

Arlene is a pensions lawyer experienced in advising trustees of occupational pension schemes. She joined BCRT as a trustee in 2018.

Gillian Johnston

Gill has 40 plus years' experience in bookkeeping, payroll and general administration. Her son, Anthony, passed away following a battle with Osteosarcoma in October 2002, and she was a founding trustee of BCRT.

James Maffin

James is a finance professional and an associate member of the Chartered Institute of Management Accountants. He is Chief Financial Officer for an award-winning manufacturing business.

Malcolm Matthews

Malcolm has experience as a charity trustee and 25 years as a director at national charities. He had leadership roles providing services and information, creating policy, campaigning and fundraising. He became involved with BCRT after his youngest son died in 2007 as a result of a Ewing sarcoma that was misdiagnosed.

Jonathan Stevenson

Jonathan is a Consultant in Orthopaedic Oncology at the Royal Orthopaedic Hospital, Birmingham, managing adult and paediatric bone and soft tissue tumours of the limbs and pelvis. He became involved with BCRT in 2019 to help promote research and awareness.

Darrell Green

Darrell's best friend passed away from primary bone cancer when they were teenagers. Darrell is now a Lecturer and Researcher at Norwich Medical School, University of East Anglia. Darrell trained in molecular genetics at Addenbrooke's Hospital in Cambridge before obtaining his PhD in molecular biology at UEA. His research combines genetics, cell and molecular biology with bioinformatics to study gene silencing in primary bone cancer. Darrell sits on the editorial board of scientific journals and on grant review panels for other cancer charities. He is a member of Norwich Cancer Research Network. He has appeared several times on TV and Radio and has presented his research across the UK and in the USA. In 2019, he was listed as a Universities UK Top 100 People "The Nation's Lifesavers". In 2020, Darrell joined BCRT as a trustee.

Damian Harper

Damian was diagnosed with Osteosarcoma in 1986 at just 17 years old. He has had a successful career, initially as a biomedical scientist, working in a pathology laboratory, then moving into project and programme management.

Alison Gartland

Alison is a Professor of Bone and Cancer Biology at The University of Sheffield and has a background of over 20 years of research into bone biology including primary bone cancer. Alison currently heads up a team of researchers looking at mechanisms of primary and metastatic bone diseases and is regularly involved in education of Medical Students at The University of Sheffield. As such Alison has knowledge of the current research landscape and also the medicine curriculum and teaching priorities for the doctors of the future. Alison is passionate about raising awareness about primary bone cancer.

Sub-Committees

The Management and Finance Committee has delegated responsibility for overseeing financial, strategic and HR matters, and also acts as the remuneration committee, making recommendations to the Board of Trustees in respect of employee salaries. The Management and Finance Committee meets at least 4 times per year. The committee members in 2020 were:

- Gillian Johnston (Committee Chair)
- Andy Lewis
- Roger Paul
- James Maffin

Recruitment and Appointment of New Trustees:

The CIO constitution requires the Board of Trustees to have at least 8 members. BCRT reviews the skills mix of the existing Board when recruiting new trustees, to ensure that their skills, personal and professional experiences are complementary to the existing board. On their appointment, new trustees are provided with, or have online access to the following documents:

- Latest audited Annual Report and Statutory Accounts
- Management accounts for the current year
- Minutes of trustee meetings for the current year
- BCRT's conflict of interest policy
- BCRT's financial procedures
- "Charity Governance Code for Larger Charities" published by the Good Governance Steering Group
- "The Essential Trustee", published by the Charity Commission.

Following their appointment, new trustees have a planned induction process during which they meet the staff team, spend time with other trustees, and get to know more about BCRT's activities. Trustees serve a 3-year term, after which they are eligible for re-election.

During 2019, a recruitment process was undertaken to appoint additional trustees with specific skills, which complemented the existing trustee board. The opportunity to become a trustee was advertised widely, on social media, the BCRT website and by relevant industry bodies. Recruitment took place towards the end of the year, and the successful applicants were appointed at the start of 2020.

Organisational Structure

The Board of Trustees meets at least 4 times a year to set the strategic direction of the charity, review ongoing operational and financial performance, approve the awarding of new research grants, and review the risks faced by the charity. The Trustees give their time freely and no trustee remuneration was paid during the year. Details of trustee expenses and related party transactions are disclosed in notes 10 and 24 of the accounts. Responsibility for the day-to-day running of the charity is delegated to the Chief Executive Officer, who is supported by a Senior Leadership Team, which comprises:

- Head of Fundraising and Communications
- Head of Research, Information and Support
- Head of Finance

The pay of the Chief Executive Officer and Senior Leadership Team is benchmarked against appropriate roles in similar charities. The charity is committed to achieving a balance between paying market rates to attract the most competent staff, and careful management of funds. A policy for staff remuneration is in place and applies to all staff employed by the charity.

The total number of staff employed at 31 December 2021 was 22 (including 7 who work part time).

The charity has a Conflict-of-Interest Policy for Trustees and Staff, and a register of interests is maintained for Trustees, the Chief Executive Officer and the Senior Leadership Team. Trustees are required to disclose all relevant interests to the Clerk to the Trustees and are required to withdraw from any decisions where an actual or potential conflict of interest may arise. Any individual with an interest in a matter being discussed at a meeting must immediately declare the interest to the meeting. The Chair of the meeting will then decide whether that individual will be entitled to vote on the matter.

Grant Making

We recognise that our ability to fund research is limited by our physical and financial resources. We aim to maximise the impact of our grants by encouraging research which is likely to win support from larger funding bodies in due course.

We believe that there is great value in collaborative research. Finding a cure depends on the cooperation of many experts, some of whom may not have worked in primary bone cancer research to date. Therefore we place special emphasis on the importance of:

- Creating the opportunity for researchers to work within primary bone cancer research
- Nurturing the careers of early-stage researchers with an interest in primary bone cancer
- Working with research teams to develop their research ideas through an innovative pilot grant scheme
- Supporting proposals which are likely to win support from larger funding bodies
- Encouraging collaboration between research groups
- Encouraging interdisciplinary team work and partnerships
- Facilitating access to primary tissue and clinical data
- Working with other charities to fund research costs

BCRT has established its grant making policy, which adheres to the recommendations set out by the Association of Medical Research Charities (AMRC) and National Institute for Health Research (NIHR) for peer review, to achieve its objects for the public benefit, and this policy is reviewed periodically. Applications are invited through calls for proposals, which then undergo a thorough review process including both review by our Independent Scientific Advisory Panel (ISAP) and external expert reviewers where necessary. The ISAP make recommendations to the trustees on the award of research grants, and the Board of Trustees approve the grants to be awarded. The ISAP consists of research professionals who are from respected centres of research throughout the UK and Europe. We also have one lay member of ISAP. BCRT is an active member of the AMRC.

The role of ISAP is to:

- Assess the validity of all research applications, taking into account the results of the external peer review process
- Interview candidates for studentships and fellowships
- Make recommendations in respect of funding projects to the Board of Trustees.

BCRT works with the primary bone cancer community and ISAP to develop our strategy to respond to areas of unmet or urgent need. BCRT works collaboratively with researchers and places emphasis on the ongoing monitoring of the impact of the research that we fund.

Risk Management

The trustees have a duty to identify and review the risks to which the charity is exposed, and to ensure that appropriate controls are in place to provide reasonable assurance against fraud and error. BCRT has a risk management policy, which reflects the commitment of the trustees to maintaining a strong risk management framework.

The trustees have examined the major strategic, business and operational risks which are faced by the charity, and confirm that there are suitable systems and procedures in place to enable those risks to be appropriately mitigated, managed and monitored. The CEO and Senior Leadership Team has a day to day responsibility to highlight any major risks that they may become aware of during the course of their duties.

The majority of BCRT's income is from voluntary donations and income from investments derived from voluntary contributions, and so there is a significant risk in being unable to maintain and grow income, in a cost-effective manner, in order to fund our charitable objectives and our 5-year strategy. To manage this risk, the charity continues to invest into the diversification of income streams and to reduce reliance on a small number of core sources of income.

Volunteers

The trustees are very appreciative of the work carried out by numerous volunteers throughout the UK and overseas and thank them for their tireless work in organising fundraising activities. There are also many volunteers that have played a role in other BCRT activities such as office administration, supporting challenges and events, conferences and Bone Cancer Awareness Week. In accordance with accepted practice, no value has been included in the financial statements to reflect the work undertaken by volunteers.

Financial Review

Income and Expenditure

BCRT celebrated its 15 year anniversary in 2021 by achieving the highest ever level of income at £4.673m. This is an increase of 70% on the previous year, and represents 20% of the total income generated since the charity was first registered in 2006. Despite the ongoing impact of the global pandemic we have continued to capitalise on virtual fundraising opportunities and engage with more new supporters, raising awareness of the signs and symptoms of primary bone cancer as well as raising funds. Many of our fundraisers have continued to organise fundraising activities during the pandemic. We have received grants and donations from a number of Trusts and Charitable Foundations, including a generous single donation of £1 million towards our research programme. We gratefully thank every single fundraiser who contributed in 2021, no matter how large or small – every donation makes such a difference in enabling BCRT to fulfil its charitable objectives.

During the year we spent £2,260K on charitable activities, including awarding grants totalling £1,334K. Charitable spend has increased by £1,310K on 2020's total as research programmes and other planned activities restarted as the global pandemic eased. Fundraising costs were £569K, 12% of total income. A surplus of £2,047K was generated in the year.

Investment Policy

BCRT's investment policy requires that there must be no direct investment into tobacco or vaping companies. The charity's investments are held in a combination of fixed interest securities, UK and overseas equities and alternative investments. The funds are held in two portfolios and managed by Brewin Dolphin. The Portfolio number 1, which comprised 58% of the total fund at 31 December 2021, has an investment mandate of 'income and capital growth with moderate investment risk', whilst the mandate for Portfolio number 2, 42% of total value at year end, is 'income and capital growth with low investment risk'.

During 2021 Portfolio number 1 made a total return of +12.78%. This compared to a total return in the MSCI Balanced Index of +12.54%. The market value of the investment portfolio as at 31 December 2021 was £2,236,537.

During 2021 the Portfolio number 2 made a total return of +7.08%. This compared to a total return in the MSCI Conservative Index of +6.89%. the market value of the investment portfolio as at 231 December 2021 was £1,614,169.

Reserves Policy

BCRT has a policy of maintaining sufficient reserves to enable the charity to meet, as a minimum, its operational costs for six months, estimated to be £1,410,000.

At the end of 2020 there was a designated reserve of £489,000 towards the costs associated with multi-year grants, including the second phase of funding for the ICONIC clinical study, and other charitable support and information costs. All of these cost were realised in 2021, leaving a balance of £nil.

During the year the trustees approved the designation of £2,620,000 towards future grant costs, including £1,200,000 towards the Hamilton Programme of Osteosarcoma research, an Early Career fellowship award, clinical trial support grants, consortia and research meeting costs and other planned grant awards. The total funds designated at 31 December 2021 was £2,620,000, of which £1,075,000 was income restricted at the point of donation.

Restricted reserves at 31 December 2021 were £1,652,514 whilst free reserves were £1,635,136. This exceeds the level required by the reserves policy. The trustees regularly monitor and review the reserves held within the context of the funds required to fulfil the objectives of the charity.

Going Concern

The trustees believe that the charity is a “going concern” based on the current financial status, the ongoing funding streams, the planned expenditure and research strategy.

Trustees Responsibility Statement

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditor

Each of the trustees confirms that so far as they are aware, there is no relevant audit information of which the charity's auditor is unaware. They have taken all the steps that they ought to have taken in order to make themselves aware of any relevant audit information and to establish that the charity's auditor are aware of that information.

Approved by order of the Board of Trustees on 30 September 2022 and signed on its behalf by
Roger Paul - trustee

Report of the Independent Auditors to the Trustees of Bone Cancer Research Trust Opinion

We have audited the financial statements of Bone Cancer Research Trust (the ‘charity’) for the year ended 31st December 2021 which comprise the Statement of Financial Activities, the Statement of Financial Position, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31st December 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Trustees' Responsibilities Statement, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- The engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations.
- We identified the laws and regulations applicable to the charity through discussions with management, and from our commercial knowledge and experience of the sector.
- We focused on specific laws and regulations which we considered may have a direct material effect on the accounts of the operations of the Charity, including the Charities Act 2011.
- We assessed the extent of compliance with laws and regulations identified above through making enquiries of management and inspecting legal correspondence.
- Identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- Making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud.
- Considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- Performed analytical procedures to identify any unusual or unexpected relationships.
- Identified and tested journal entries and identified any significant transactions that were unusual or outside the normal course of business.
- Investigated the rationale behind significant or unusual transactions.
- Challenged assumptions and judgements made by management in determining significant accounting estimates.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed audit procedures which included, but were not limited to:

- Agreeing financial statements disclosures to underlying supporting documentation.
- Discussions with management of known or suspected instances of non-compliance with laws and regulations.
- Reading the minutes of meetings of those charged with governance.
- Reviewing correspondence with HMRC, relevant regulators including the Charities Commission and the charity's legal advisors.

At the completion stage of the audit, the engagement partner's review included ensuring that the team had approached their work with appropriate professional scepticism and thus the capacity to identify non-compliance with laws and regulations and fraud.

There are inherent limitations in the audit procedures described above and the further removed non-compliance of laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement relating to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Christopher Darwin FCA (Senior Statutory Auditor)
For and on behalf of Thomas Coombs Limited
Statutory Auditor
Chartered Accountants
3365 The Pentagon
Century Way
Thorpe Park
Leeds
West Yorkshire
LS15 8ZB

Date: 30 September 2022

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST DECEMBER 2021

		UNRESTRICTED FUNDS	RESTRICTED FUNDS	TOTAL FUNDS 2021	TOTAL FUNDS 2020
	NOTES	£	£	£	£
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	2,655,762	1,952,988	4,608,750	2,718,008
Other trading activities	3	13,757	-	13,757	6,292
Investment income	4	50,516	-	50,516	31,742
Total		2,720,035	1,952,988	4,673,023	2,756,042
EXPENDITURE ON					
Income generation	5	569,275	-	569,275	400,027
Charitable activities	6				
Research		584,901	906,035	1,490,936	319,094
Awareness		534,302	-	534,302	449,377
Information		98,497	-	98,497	76,254
Support		87,575	34,528	122,103	94,977
Governance		13,752	-	13,752	9,952
Total		1,888,302	940,563	2,828,865	1,349,681
NET INCOME/(EXPENDITURE) BEFORE INVESTMENT GAINS/(LOSSES)					
		831,733	1,012,425	1,844,158	1,406,361
Net gains on investments		203,075	-	203,075	33,991
NET INCOME		1,034,808	1,012,425	2,047,233	1,440,352
RECONCILIATION OF FUNDS					
Total funds brought forward		2,172,436	640,089	2,812,525	1,372,173
TOTAL FUNDS CARRIED FORWARD		3,207,244	1,652,514	4,859,758	2,812,525

STATEMENT OF FINANCIAL POSITION 31ST DECEMBER 2021

		UNRESTRICTED FUNDS	RESTRICTED FUNDS	TOTAL FUNDS 2021	TOTAL FUNDS 2020
	NOTES	£	£	£	£
FIXED ASSETS					
Intangible assets	13	6,463	-	6,463	-
Tangible assets	14	20,645	-	20,645	8,309
Investments	15	3,847,964	-	3,847,964	2,090,680
		3,875,072	-	3,875,072	2,098,989
CURRENT ASSETS					
Stocks	16	176,920	-	176,920	128,742
Debtors	17	437,491	-	437,491	224,174
Cash at bank and in hand		534,069	1,652,514	2,186,583	1,048,842
		1,148,480	1,652,514	2,800,994	1,401,758
CREDITORS					
Amounts falling due within one year	18	(1,286,617)	-	(1,286,617)	(669,408)
		(138,137)	1,652,514	1,514,377	732,350
NET CURRENT ASSETS					
		(138,137)	1,652,514	1,514,377	732,350
TOTAL ASSETS LESS CURRENT LIABILITIES					
		3,736,935	1,652,514	5,389,449	2,831,339
CREDITORS					
Amounts falling due after more than one year	19	(529,691)	-	(529,691)	(18,814)
		(529,691)	-	(529,691)	(18,814)
NET ASSETS					
		3,207,244	1,652,514	4,859,758	2,812,525
FUNDS					
Unrestricted funds	21				
- Free reserves				1,635,136	1,675,127
- Fixed asset reserve				27,108	8,309
- Designated reserve	23			1,545,000	489,000
Restricted funds	22			1,652,514	640,089
TOTAL FUNDS					
				4,859,758	2,812,525

The financial statements were approved by the Board of Trustees and authorised for issue on 30 September 2022 and were signed on its behalf by:

Roger Paul - trustee

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST DECEMBER 2021

		2021	2020
	NOTES	£	£
Cash flows from operating activities:			
Cash generated from operations	1	2,665,267	1,237,873
Net cash provided by operating activities		2,665,267	1,237,873
Cash flows from investing activities			
Purchase of intangible fixed assets		(6,600)	-
Purchase of tangible fixed assets		(17,233)	(318)
Purchase of fixed asset investments		(1,708,108)	(1,095,887)
Sale of fixed asset investments		153,899	322,255
Investment income		50,516	31,742
Net cash used in investing activities		(1,527,526)	(742,208)
Change in cash and cash equivalents in the reporting period		1,137,741	495,665
Cash and cash equivalents at the beginning of the reporting period		1,048,842	553,177
Cash and cash equivalents at the end of the reporting period		2,186,583	1,048,842

NOTES TO THE STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST DECEMBER 2021

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2021	2020
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	2,047,233	1,440,352
Adjustments for:		
Depreciation charges	4,897	3,584
Gain on investments	(3,527)	(2,840)
Amortisation charges	137	5,048
Unrealised loss/(gain) on investments	(199,548)	(31,151)
Investment income	(50,516)	(31,742)
Increase in stocks	(48,178)	(76,338)
Increase in debtors	(213,317)	(4,885)
Increase/(decrease) in creditors	1,128,086	(64,155)
Net cash provided by operations	2,665,267	1,237,873

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST DECEMBER 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The trustees consider that there are no material uncertainties about the Charity's ability to continue for a period of not less than 12 months from the date of the approval of the financial statements. Accordingly the financial statements have been prepared on the going concern basis.

Income

Donations and sponsored events are included in the Statement of Financial Activities when:

- the Charity is told it is to receive the gift or donation
- the trustees are reasonably certain of the amount to be received
- the trustees are reasonably certain they will receive the money and
- any conditions for receipt are met

Income from challenge events is recognised when the event takes place. Any income received in relation to events taking place in future years is held as deferred income until the event takes place.

Legacies are recognised when it is probable that they will be received. Receipt is normally probable when:

- there has been grant of a probate;
- the executors have established that there are sufficient assets in the estate after settling any liabilities to pay the legacy; and
- any conditions attached to the legacy are either within the control of the Charity or have been met.

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the company will comply with conditions attaching to them and the grants will be received using the accruals model.

No amounts are included in the financial statements for services donated by volunteers.

Interest is accounted for on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Irrecoverable VAT is charged against the category of resources expended for which it was incurred.

The costs of generating income consist of investment management fees and those costs incurred attracting voluntary income and activities for generating funds, such as events.

Costs of charitable activities include grants made and an apportionment of overheads and administration costs.

Grants payable are payments made to third parties in the furtherance of the charitable objectives of the Charity. Single or multi-year grants are accounted for where either the recipient has a reasonable expectation that they will receive a grant and the trustees have agreed to pay the grant without condition, or the recipient has a reasonable expectation that they will receive a grant and any condition attaching to the grant is outside of the control of the Charity.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to external inspection and legal fees together with an apportionment of overhead and administration costs.

Critical accounting estimates and judgements

In the application of the charities accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Critical estimates and judgements

Allocation of administration costs

Administration costs are allocated between the various activities of the group based on the weighting each activity has within total expenditure. The allocation of these costs is considered to be critical to the accounts because they have the ability to materially alter the allocation of costs between expenditure on raising funds and expenditure on charitable activities.

The activities of the charity are categorised as follows:

Income generation	- expenditure incurred in order to raise funds for charitable purposes.
Research	- grant funding research into funding a cure for primary bone cancer.
Awareness	- increasing survival rates through raising awareness of primary bone cancer.
Information	- providing accurate and reliable information across all forms of primary bone cancer.
Support	- improving the access to primary bone cancer support for all patients, family members, carers and friends.

The breakdown of administration costs and how these were allocated between governance and other administration costs is based on the following rates:

Income generation	37.5% (2020: 29%)	Information	6.7% (2020: 6%)
Research	10.6% (2020: 24%)	Support	8.9% (2020: 7%)
Awareness	36.3% (2020: 34%)		

In previous years, the costs of grants awarded, within research activities have been included when calculating the breakdown of administration costs. In 2021 the trustees decided that it would be appropriate to exclude grants awarded from this calculation to avoid significant year on year variances in the breakdown of administration costs. This approach will continue in future years.

Intangible fixed assets

Amortisation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Website - 25% on cost

Tangible fixed assets

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses. Costs includes costs directly attributable to making the asset capable of operating as intended.

Depreciation is provided to write off the cost less the estimated residual of tangible fixed assets by equal instalments over their estimated useful economic lives as follows:

Fixtures and fittings - 25% on cost **Computer equipment** - 33% on cost and 25% on cost

Stocks

Stocks are valued at weighted average cost, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Investments

Investments held by the charity are shares which are publicly traded. Investments are recognised initially at fair value which is normally the transaction price including transaction costs. Subsequently, they are measured at fair value with changes recognised in 'net gains / (losses) on investments' in the SoFA.

Financial instruments other than investments

The charity has financial assets and financial liabilities of a kind that qualify as basic and complex financial instruments. Basic financial instruments are measured at their settlement value in the case of current assets and liabilities and at discounted settlement value in the case of creditors falling due after more than one year.

Status

The Bone Cancer Research Trust is a Charitable Incorporated Organisation (CIO), the liability is therefore restricted. If the CIO is wound up, the members of the CIO have no liability to contribute to its assets and no personal responsibility for settling its debts and liabilities.

Volunteers

The value of services provided by volunteers is not incorporated into these financial statements. Further details of the contribution made by volunteers can be found in the trustees' annual report.

Where services are provided to the Charity as a donation that would normally be purchased from a supplier, this contribution is included in the financial statements at an estimate based on the value of the contribution to the Charity.

Pension costs

The Charity contributes to defined contribution schemes on behalf of some of its employees. These contributions are charged to the SoFA when accrued.

2. DONATIONS AND LEGACIES

	2021	2020
	£	£
Event income	2,790,846	1,703,775
Donations	1,816,789	960,936
Grants	1,115	53,297
Total	4,608,750	2,718,008

Grants received, included in the above, are as follows:

	2021	2020
	£	£
Furlough grant	1,115	53,297
Total	1,115	53,297

3. OTHER TRADING ACTIVITIES

	2021	2020
	£	£
Other trading income	13,757	6,292
Total	13,757	6,292

4. INVESTMENT INCOME

	2021	2020
	£	£
Investment income	50,516	31,742
Total	50,516	31,742

5. INCOME GENERATION

Raising donations and legacies

	2021	2020
	£	£
Staff costs	234,934	209,635
Event costs	121,909	70,391
Other trading costs	6,561	3,108
Other fundraising costs	75,010	28,686
Administration costs	130,861	88,207
Total	569,275	400,027

6. CHARITABLE ACTIVITIES COSTS

	DIRECT COSTS	GRANT FUNDING OF ACTIVITIES (SEE NOTE 7)	ADMINISTRATION COSTS (SEE NOTE 8)	TOTALS
	£	£	£	£
Research	131,623	1,327,298	32,015	1,490,936
Awareness	425,022	-	109,280	534,302
Information	78,367	-	20,130	98,497
Support	95,405	-	26,698	122,103
Governance	-	-	13,752	13,752
Total	730,417	1,327,298	201,875	2,259,590
Total 2020	567,015	183,027	199,612	949,654

7. GRANTS AWARDED TO INSTITUTIONS IN THE YEAR

	2021			2020
	£			£
Research	1,327,298			183,027
	2021 Unrestricted	2021 Restricted	2021 Total	2020
Prof Sibylle Mitnacht, UCL Cancer Institute, Developing Genome-informed treatment to improve outcome in Osteosarcoma	239,649	9,555	249,204	37,139
Dr William Cross UCL, Posthumous evaluation of a high-grade widely disseminated chondrosarcoma through analysis of its evolutionary history	-	-	-	70,000
Prof Paul Cool, Sample collection support - Oswestry	-	-	-	21,295
Dr Katie Finegan, University of Manchester, Targeting the MEK5-ERK5 pathway	-	-	-	23,432
Dr Mark Morris, Research Institute of Health Science, University of Wolverhampton, Identification of novel biomarkers for the management of adamantinoma	-	-	-	21,000
Professor Alison Gartland, The Mellanby Centre for Bone Research, Department of Oncology and Metabolism, Sheffield University, The Role of Oestrogen in Chondrosarcoma Using Patient-Derived Xenograft Mouse models: A Pilot Study	-	16,667	16,667	20,000
Prof Aykut Üren, Georgetown University, Lombardi Comprehensive Cancer Centre, Second Generation Clofarabine Derivatives as CD99 Inhibitors	-	70,000	70,000	-
Mr Jonathan Stevenson, The Royal National Orthopaedic Hospital NHS Foundation Trust, Birmingham, sample collection support	19,660	10,237	29,897	-
Prof Adrienne Flanagan, Royal National Orthopaedics Hospital Brockley Hill, Stanmore, sample collection support	28,396	-	28,396	-
Prof Robert Falconer, Institute of Cancer Therapeutics, University of Bradford, Development of a targeted methotrexate prodrug with enhanced therapeutic index for osteosarcoma	-	16,626	16,626	-
Dr Darrell Green, Biomedical Research Centre, Norwich Medical School, TP53 Restoration using mRNA Vaccine Technology	11,000	9,000	20,000	-
Dr Karen Shah, The Mellanby Centre for Bone Research, Department of Oncology and Metabolism, Sheffield University, Delineating the role of hypoxic extracellular vesicles in pulmonary metabolism	-	19,867	19,867	-
Dr Kogularamanan Suntharalingam, School for Chemistry, University of Leicester, Bone-seeking Metal-based Drugs to overcome Chemotherapy Resistant Osteosarcoma Sub-populations	-	20,000	20,000	-
Professor Gareth Veal, Newcastle University, Optimising the Treatment of Teenagers and Young Adults with Ewing Sarcoma through an Increased Understanding of Clinical Pharmacology and Toxicity Biomarker	-	145,530	145,530	-

Continued...

			2021	2020
			£	£
	2021 Unrestricted	2021 Restricted	2021 Total	2020
Dr Sandra Strauss, UCL Cancer Institute, ICONIC – Improving Outcome through Collaboration in Osteosarcoma	-	175,000	175,000	-
Dr Olivier Pardo, Imperial College, Division of Cancer, Modulation of Interferon Gamma-mediated Signalling and immune Response by Fibroblast Growth Factor 2 in Osteosarcoma	173,013	76,768	249,781	-
Dr Martin Pule, UCL Cancer Institute, Towards Engineered T Cells for Osteosarcoma	4,000	30,614	34,614	-
Dr Sandra Strauss, UCL Cancer Institute, Improving outcome in Sarcoma through Analysis and interrogation of National Cancer Data	43,082	-	43,082	-
Dr Sandra Strauss, UCL Cancer institute, Euro Ewing Consortium	-	36,091	36,091	-
Early Diagnosis Patient Grant	6,000	-	6,000	-
Mr Kenneth Rankin, Northern Institute for Cancer Research, Newcastle University, sample collection support	11,000	5,000	16,000	-
Prof Susan Burchill, Leeds Institute of Medical Research, International Collaboration to Optimise	-	149,622	149,622	-
Patient Travel Support Grant	2,520	-	2,520	2,201
Prof Sue Burchill, University of Leeds, Modelling Ewing's sarcoma heterogeneity and tumour microenvironment to improve outcomes	-	-	-	(2,198)
Dr Helen Roberts (née Owen), Middlesex University London, MicroRNA Regulation of Autophagy-Induced Chemoresistance in Osteosarcoma	-	-	-	(569)
Prof Sue Burchill, University of Leeds, Can we reliably detect viable, dying or dead Ewing's sarcoma cells in peri-tumoural tissue following induction chemotherapy?	-	-	-	(1,902)
Prof Alison Gartland, The University of Sheffield, Osteo, Purigenic signalling in osteosarcoma.	-	-	-	(2,131)
Professor Dominique Heymann, The University of Sheffield, Osteo, Early events of recurrent disease and metastatic dissemination in osteosarcoma: pre-clinical assessment and clinical proof-of-concept.	-	-	-	(4)
Prof Sue Burchill, University of Leeds, Ewings Ideas, Identification of the lead candidate NRXN1 isoform as a prognostic biomarker and a novel target for therapy	-	-	-	(4)
Grant refund - Dr Sandra Strauss, Investigation of CL67 as a first-in-class novel inhibitor of the HIF 1alpha pathway in osteosarcoma	-	-	-	(5,232)
Dr Jessica Bates, University College London Hospital, Ewing sarcoma project	(1,599)	-	(1,599)	-

Continued...

	2021	2020		
	£	£		
	2021 Unrestricted	2021 Restricted	2021 Total	2020
Restricted funding allocated to payments of existing grants meeting the specific restrictions	(115,458)	115,458	-	-
	421,263	906,035	1,327,298	183,027

8. ADMINISTRATION COSTS

	MANAGEMENT	INVESTMENT MANAGEMENT COSTS	GOVERNANCE COSTS	TOTALS
	£	£	£	£
Research	32,015	-	-	32,015
Awareness	109,280	-	-	109,280
Information	20,130	-	-	20,130
Support	26,698	-	-	26,698
Income generation	112,627	18,234	-	130,861
Governance	-	-	13,752	13,752
Total	300,750	18,234	13,752	332,736
Total 2020	268,639	9,228	9,952	287,819

Administration costs, included in the above, are as follows:

	RESEARCH	AWARENESS	INFORMATION	SUPPORT
	£	£	£	£
Wages	7,157	24,426	4,499	5,966
Social security	584	1,993	367	487
Pensions	173	592	109	145
Redundancy costs	-	-	-	-
Rent, rates and water	2,541	8,672	1,597	2,118
Telephone	1,019	3,479	641	850
Postage and stationery	1,807	6,181	1,140	1,514
Sundries	1,672	5,710	1,052	1,395
Travel and subsistence	293	1,002	185	244
Software licences	2,864	9,772	1,800	2,387
Recruitment and human resources costs	1,579	5,387	992	1,316
Stock management	11,311	38,604	7,110	9,430
Bank charges	90	304	56	74
Legal fees	389	1,329	245	325
Amortisation of intangible fixed assets	15	50	9	12
Depreciation of tangible fixed assets	521	1,779	328	435
Portfolio management	-	-	-	-
Trustees' expenses and meeting costs	-	-	-	-
Auditors' remuneration	-	-	-	-
Accountancy and legal fees	-	-	-	-
Total	32,015	109,280	20,130	26,698
Total 2020	64,477	90,800	15,311	19,072

Continued...

	INCOME GENERATION	GOVERNANCE	2021 TOTAL ACTIVITIES	2020 TOTAL ACTIVITIES
	£	£	£	£
Wages	25,171	-	67,219	63,661
Social security	2,054	-	5,485	5,385
Pensions	610	-	1,629	1,359
Redundancy costs	-	-	-	4,295
Rent, rates and water	8,936	-	23,864	23,130
Telephone	3,585	-	9,574	9,771
Postage and stationery	6,383	-	17,025	14,060
Sundries	5,884	-	15,713	7,899
Travel and subsistence	1,032	-	2,756	3,845
Software licences	10,070	-	26,893	32,035
Recruitment and human resources costs	5,552	-	14,826	8,533
Stock management	39,781	-	106,326	82,987
Bank charges	314	-	838	785
Legal fees	1,370	-	3,658	2,261
Amortisation of intangible fixed assets	51	-	137	5,048
Depreciation of tangible fixed assets	1,834	-	4,897	3,585
Portfolio management	18,234	-	18,234	9,228
Trustees' expenses and meeting costs	-	260	260	1,928
Auditors' remuneration	-	9,100	9,100	5,319
Accountancy and legal fees	-	4,392	4,392	2,705
Total	130,861	13,752	332,736	287,819
Total 2020	88,207	9,952	287,819	

9. AUDITORS' REMUNERATION

	2021	2020
	£	£
Fees payable to the charity's auditors for the audit of the charity's financial statements	9,100	5,319

10. TRUSTEES' REMUNERATION AND BENEFITS

The average number of trustees in the year were 11 (2020: 13).

There were no trustee's remuneration or other benefits for the year ended 31st December 2021 nor for the year ended 31st December 2020.

All trustees give their time freely and no trustee remuneration was paid in the year. During the year monetary donations made by trustees to the Charity totalled £668 (2020: £1,142). A number of trustees have connections to organisations which donate funds to the Trust. Further details are provided in note 24.

Trustees' expenses

Reimbursed expenses, which are all subject to the charity's processes of internal controls, do not form part of the remuneration and are not included above. During the period, trustee expenses of £260 (2020: £1,634) were reimbursed to two trustees (2020: six trustees).

11. STAFF COSTS

	2021	2020
	£	£
Wages and salaries	592,469	526,537
Social security costs	52,529	45,088
Other pension costs	15,382	13,769
Redundancy costs	-	4,295
Total	660,380	589,689

The average monthly number of employees during the year was as follows:

	2021	2020
Permanent staff	20	18

The average full time equivalent of employees during the year was 18.3 (2020: 17.4).

No employees received emoluments in excess of £60,000.

The Trust considers its key management personnel comprise the trustees and its Senior Management Team. The total employment costs to the charity of the key management personnel were £156,923 (2020: £141,609).

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	UNRESTRICTED FUNDS	RESTRICTED FUNDS	TOTAL FUNDS
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	2,148,648	569,360	2,718,008
Other trading activities	6,292	-	6,292
Investment income	31,742	-	31,742
Total	2,186,682	569,360	2,756,042
EXPENDITURE ON			
Income generation	400,027	-	400,027
Charitable activities			
Research	181,074	138,020	319,094
Awareness	429,377	20,000	449,377
Information	76,254	-	76,254
Support	23,624	71,353	94,977
Admin	9,952	-	9,952
Total	1,120,308	229,373	1,349,681
Net gains on investments	33,991	-	33,991
NET INCOME	1,100,365	339,987	1,440,352
RECONCILIATION OF FUNDS			
Total funds brought forward	1,072,071	300,102	1,372,173
TOTAL FUNDS CARRIED FORWARD	2,172,436	640,089	2,812,525

13. INTANGIBLE FIXED ASSETS

WEBSITE COSTS	
	£
COST	
At 1st January 2021	38,187
Additions	6,600
At 31st December 2021	44,787
AMORTISATION	
At 1st January 2021	38,187
Charge for year	137
At 31st December 2021	38,324
NET BOOK VALUE	
At 31st December 2021	6,463
At 31st December 2020	-

14. TANGIBLE FIXED ASSETS

	FIXTURES AND FITTINGS	COMPUTER EQUIPMENT	TOTALS
	£	£	£
COST			
At 1st January 2021	11,488	20,075	31,563
Additions	384	16,849	17,233
At 31st December 2021	11,872	36,924	48,796
DEPRECIATION			
At 1st January 2021	4,432	18,822	23,254
Charge for year	2,562	2,335	4,897
At 31st December 2021	6,994	21,157	28,151
NET BOOK VALUE			
At 31st December 2021	4,878	15,767	20,645
At 31st December 2020	7,056	1,253	8,309

15. FIXED ASSET INVESTMENTS

	LISTED INVESTMENTS	CASH AND SETTLEMENTS PENDING	TOTALS
	£	£	£
MARKET VALUE			
At 1st January 2021	2,036,771	53,909	2,090,680
Additions	1,716,470	(8,362)	1,708,108
Disposals	(150,372)	-	(150,372)
Revaluations	199,548	-	199,548
At 31st December 2021	3,802,417	45,547	3,847,964
NET BOOK VALUE			
At 31st December 2021	3,802,417	45,547	3,847,964
At 31st December 2020	2,036,771	53,909	2,090,680

At 31st December 2021 no individual investment represented more than 5% of the total investment portfolio valuation.

The historical cost at 31st December 2021 is £3,392,375 (2020: £1,807,333).

All investments are carried at their fair value. Investment in equities and fixed interest securities are all traded in quoted public markets, primarily the London Stock Exchange. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The significance of financial instruments to the ongoing financial sustainability of the Trust is considered in the financial review and investment policy and performance sections of the Trustees' Annual Report.

The main risk to the Charity from financial instruments arises from uncertain investment markets resulting in variable income and capital returns from the portfolio of assets.

Currency translation risks remain for those companies and bonds that are exposed to overseas earnings and assets.

Liquidity risk is anticipated to be low as all assets are traded on recognised exchanges with good liquidity and high trading volumes. The Charity's portfolio has no material investment holdings in markets subject to exchange controls or trading restrictions.

The Charity manages investment risk by appointing professional investment managers and operating an investment policy that provides for a high degree of diversification of holdings within investment asset classes that are quoted on recognised stock exchanges.

The Charity does not make use of derivatives and similar complex financial instruments as it takes the view that investments are held for their longer term total return.

16. STOCKS

	2021	2020
	£	£
Stocks of fund raising items	176,920	128,742

17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Other debtors	25,710	21,051
Accrued income, including gift aid receivable	138,968	117,983
Prepaid event costs	272,813	85,140
Total	437,491	224,174

18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Trade creditors	49,266	5,532
Taxation and social security	19,012	13,567
Grants payable	1,134,977	617,720
Deferred event income	23,293	5,876
Other creditors	60,069	26,713
Total	1,286,617	669,408

19. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2021	2020
	£	£
Grants payable	529,691	18,814
Reconciliation of Grants Awarded	2021	2020
Opening liability obligation	636,534	670,229
Research grants awarded in the year	1,327,298	195,067
Research grants refunded in the year	-	(5,232)
Provisions no longer required	(1,599)	(6,808)
Paid during the year	(299,164)	(216,722)
Closing liability obligation	1,664,668	636,534
Split as:		
Due within one year	1,134,977	617,720
Due after more than one year	529,691	18,814

20. LEASING AGREEMENTS

The following operating lease payments are committed to be paid:

	LAND AND BUILDINGS		OTHER	
	2021	2020	2021	2020
	£	£	£	£
Expiring:				
Within one year	16,797	16,797	818	6,161
Between one and five years	18,324	35,121	576	1,394
Total	35,121	51,918	1,394	7,555

21. MOVEMENT IN FUNDS

	AT 1/1/21	NET MOVEMENT IN FUNDS	31/12/21
	£	£	£
Unrestricted funds			
General fund	2,172,436	1,034,808	3,207,244
Restricted funds			
Ewing Sarcoma			
Liberty's Legacy	188,055	872	188,927
Frank's Fund	144,136	(35,098)	109,038
Freddie's Future	36,045	15,425	51,470
Fitzzy's Fund	41,979	58,058	100,037
Ewing Sarcoma Research Trust	22,198	(20,000)	2,198
Other funds restricted to research into Ewing Sarcoma	39,047	3,415	42,462
Osteosarcoma			
Hamilton Family Research Fund	-	1,079,500	1,079,500
In support of Mary Collard	27,748	(27,427)	321
Tom Stead	7,687	(2,788)	4,899
Anthony Pilcher Bone Cancer Trust	5,973	(5,855)	118
Jess Gower	3,241	(3,183)	58
Tom Hunt	2,711	10,663	13,374
Rhodri Jones	6,125	(6,013)	112
Other funds restricted to research into Osteosarcoma	10,911	(10,419)	492
Other Research			
The Liz Clarke-Saul Fund	10,473	13,099	23,572
Michael Davie Research Foundation	-	-	-
Robert Luff Foundation	-	-	-
Other funds restricted to research	435	(7,659)	(7,224)
Infrastructure Grant			
QBE Foundation	737	(737)	-
PF Charitable Trust	11,000	-	11,000
Doris Field Charitable Trust	7,500	(2,500)	5,000
Barbour Foundation	-	-	-
Edward Cadbury Trust	5,000	(5,000)	-
GJW Turner Charitable Trust	-	2,500	2,500
Margaret Butters Reekie	10,000	(10,000)	-
Other funds restricted to infrastructure grants	1,242	7,000	8,242
Methotrexate Prodrug			
Balcombe Trust	10,000	(10,000)	-
The Charity of Stella Symons	10,000	(10,000)	-
Support, Information and Awareness			
Takeda	20,727	(12,352)	8,375
My Blue Heart	4,309	(4,309)	-
James Tudor Foundation	7,100	(1,458)	5,642
February Foundation	-	-	-
St James' Place	2,500	(2,500)	-
David Brooke Foundation	-	2,403	2,403
Other funds restricted to support, information and awareness	3,210	(3,212)	(2)
	640,089	1,012,425	1,652,514
TOTAL FUNDS	2,812,525	2,047,233	4,859,758

21. MOVEMENT IN FUNDS - CONTINUED

Net movement in funds, included in the above are as follows:

	INCOMING RESOURCES	RESOURCES EXPENDED	GAINS AND LOSSES	MOVEMENT IN FUNDS
	£	£	£	£
Unrestricted funds				
General fund	2,720,035	(1,888,302)	203,075	1,034,808
Restricted funds				
Ewing Sarcoma				
Liberty's Legacy	135,872	(135,000)	-	872
Frank's Fund	95,993	(131,091)	-	(35,098)
Freddie's Future	65,425	(50,000)	-	15,425
Fitzzy's Fund	113,588	(55,530)	-	58,058
Ewing Sarcoma Research Trust	14,963	(34,963)	-	(20,000)
Other funds restricted to research into Ewing Sarcoma	33,036	(29,621)	-	3,415
Osteosarcoma				
Hamilton Family Research Fund	1,250,000	(170,500)	-	1,079,500
In support of Mary Collard	58,087	(85,514)	-	(27,427)
Tom Stead	16,096	(18,884)	-	(2,788)
Anthony Pilcher Bone Cancer Trust	9,545	(15,400)	-	(5,855)
Jess Gower	8,045	(11,228)	-	(3,183)
Tom Hunt	-	10,663	-	10,663
Rhodri Jones	8,587	(14,600)	-	(6,013)
Other funds restricted to research into Osteosarcoma	39,810	(50,229)	-	(10,419)
Other Research				
The Liz Clarke-Saul Fund	13,099	-	-	13,099
Michael Davie Research Foundation	10,000	(10,000)	-	-
Robert Luff Foundation	10,000	(10,000)	-	-
Other funds restricted to research	16,742	(24,401)	-	(7,659)
Infrastructure Grant				
QBE Foundation	-	(737)	-	(737)
PF Charitable Trust	10,000	(10,000)	-	-
Doris Field Charitable Trust	2,000	(4,500)	-	(2,500)
Barbour Foundation	5,000	(5,000)	-	0
Edward Cadbury Trust	-	(5,000)	-	(5,000)
GJW Turner Charitable Trust	5,000	(2,500)	-	2,500
Margaret Butters Reekie	-	(10,000)	-	(10,000)
Other funds restricted to infrastructure grants	9,000	(2,000)	-	7,000
Methotrexate Prodrug				
Balcombe Trust	10,000	(20,000)	-	(10,000)
The Charity of Stella Symons	-	(10,000)	-	(10,000)
Support, Information and Awareness				
Takeda	-	(12,352)	-	(12,352)
My Blue Heart	-	(4,309)	-	(4,309)
James Tudor Foundation	-	(1,458)	-	(1,458)
February Foundation	5,000	(5,000)	-	-
St James' Place	2,500	(5,000)	-	(2,500)
David Brooke Foundation	2,600	(197)	-	2,403
Other funds restricted to support, information and awareness	3,000	(6,212)	-	(3,212)
	1,952,988	(940,563)	-	1,012,425
TOTAL FUNDS	4,673,023	(2,828,865)	203,075	2,047,233

21. MOVEMENT IN FUNDS - CONTINUED

	AT 1/1/20	NET MOVEMENT IN FUNDS	31/12/20
	£	£	£
Unrestricted funds			
General fund	1,072,071	1,100,365	2,172,436
Restricted funds			
Ewing sarcoma			
Liberty's Legacy	109,798	78,257	188,055
Frank's Fund	81,934	62,202	144,136
Freddie's Future	-	36,045	36,045
Fitzzy's Fund	-	41,979	41,979
Ewing Sarcoma Research Trust	2,198	20,000	22,198
Other funds restricted to research into Ewing Sarcoma	23,333	15,714	39,047
Osteosarcoma			
Hamilton Family Research Fund	-	-	-
In support of Mary Collard	725	27,023	27,748
Tom Stead	786	6,901	7,687
Anthony Pilcher Bone Cancer Trust	100	5,873	5,973
Jess Gower	-	3,241	3,241
Tom Hunt	13,149	(10,438)	2,711
Rhodri Jones	20	6,105	6,125
Other funds restricted to research into Osteosarcoma	2,013	8,898	10,911
Other Research			
The Liz Clarke-Saul Fund	22,498	(12,025)	10,473
Michael Davie Research Foundation	-	-	-
Robert Luff Foundation	-	-	-
Other funds restricted to research	2,794	(2,359)	435
Infrastructure Grant			
QBE Foundation	13,027	(12,290)	737
PF Charitable Trust	1,000	10,000	11,000
Doris Field Charitable Trust	5,000	2,500	7,500
Barbour Foundation	-	0	-
Edward Cadbury Trust	-	5,000	5,000
GJW Turner Charitable Trust	-	0	-
Margaret Butters Reekie	-	10,000	10,000
Other funds restricted to infrastructure grants	1,000	242	1,242
Methotrexate Prodrug			
Balcombe Trust	-	10,000	10,000
The Charity of Stella Symons	-	10,000	10,000
Support, Information and Awareness			
Takeda	20,727	-	20,727
My Blue Heart	-	4,309	4,309
James Tudor Foundation	-	7,100	7,100
February Foundation	-	-	-
St James' Place	-	2,500	2,500
David Brooke Foundation	-	-	-
Other funds restricted to support, information and awareness	-	3,210	3,210
	300,102	339,987	640,089
TOTAL FUNDS	1,372,173	1,440,352	2,812,525

21. MOVEMENT IN FUNDS - CONTINUED

Net movement in funds, included in the above are as follows:

	INCOMING RESOURCES	RESOURCES EXPENDED	GAINS AND LOSSES	MOVEMENT IN FUNDS
	£	£	£	£
Unrestricted funds				
General fund	2,186,682	(1,120,308)	33,991	1,100,365
Restricted funds				
Ewing sarcoma				
Liberty's Legacy	85,725	(7,468)	-	78,257
Frank's Fund	72,139	(9,937)	-	62,202
Freddie's Future	36,045	-	-	36,045
Fitzzy's Fund	41,979	-	-	41,979
Ewing Sarcoma Research Trust	20,000	-	-	20,000
Other funds restricted to research into Ewing Sarcoma	15,714	-	-	15,714
Osteosarcoma				
Hamilton Family Research Fund	-	-	-	-
In support of Mary Collard	50,992	(23,969)	-	27,023
Tom Stead	9,901	(3,000)	-	6,901
Anthony Pilcher Bone Cancer Trust	5,873	-	-	5,873
Jess Gower	3,241	-	-	3,241
Tom Hunt	-	(10,438)	-	(10,438)
Rhodri Jones	11,105	(5,000)	-	6,105
Other funds restricted to research into Osteosarcoma	14,068	(5,170)	-	8,898
Other Research				
The Liz Clarke-Saul Fund	32,407	(44,432)	-	(12,025)
Michael Davie Research Foundation	-	-	-	-
Robert Luff Foundation	-	-	-	-
Other funds restricted to research	10,957	(13,316)	-	(2,359)
Infrastructure Grant				
QBE Foundation	-	(12,290)	-	(12,290)
PF Charitable Trust	10,000	-	-	10,000
Doris Field Charitable Trust	2,500	-	-	2,500
Barbour Foundation	-	-	-	-
Edward Cadbury Trust	5,000	-	-	5,000
GJW Turner Charitable Trust	-	-	-	-
Margaret Butters Reekie	10,000	-	-	10,000
Other funds restricted to infrastructure grants	3,240	(2,998)	-	242
Methotrexate Prodrug				
Balcombe Trust	10,000	-	-	10,000
The Charity of Stella Symons	10,000	-	-	10,000
Support, Information and Awareness				
Takeda	-	-	-	-
My Blue Heart	4,309	-	-	4,309
James Tudor Foundation	7,100	-	-	7,100
February Foundation	-	-	-	-
St James' Place	2,500	-	-	2,500
David Brooke Foundation	-	-	-	-
Other funds restricted to support, information and awareness	94,565	(91,355)	-	3,210
	569,360	(229,373)	-	339,987
TOTAL FUNDS	2,756,042	(1,349,681)	33,991	1,440,352

22. RESTRICTED FUNDS

Ewing Sarcoma

The Liberty's Legacy Restricted Fund represents monies restricted for research into Ewing Sarcoma.

Franks fund represent monies restricted for research into Ewing Sarcoma.

Freddie's Future Restricted Fund represents monies restricted for research into Ewing Sarcoma.

Fitzzy's Fund represents monies restricted for research into Ewing Sarcoma.

The Ewing's Sarcoma Research Trust Restricted Fund represents monies restricted for research into Genotype and Phenotype Self-renewing cancer-initiating Ewing Sarcoma, the National Ewing Sarcoma Multi-Disciplinary Team Meeting and oncolytic virus therapy for Ewing sarcoma.

Other funds represent monies restricted for research into Ewing Sarcoma.

Osteosarcoma

The Hamilton Family Research Fund represents funds restricted for research into Osteosarcoma.

The Mary Collard Restricted Fund represents funds restricted for research into Osteosarcoma.

The Tom Stead Restricted Fund represents monies restricted for research into Osteosarcoma.

The Anthony Pilcher Restricted Fund represents monies restricted for research into Osteosarcoma.

The Jess Gower Restricted Fund represents monies restricted for research into Osteosarcoma.

The Tom Hunt Restricted Fund represents monies restricted for research into Osteosarcoma.

The Rhodri Jones Restricted Fund represents monies restricted for research into Osteosarcoma

Other funds represent monies restricted for research into Osteosarcoma.

Infrastructure grant

The QBE Foundation Restricted Fund represents monies restricted to the 2018 Birmingham Infrastructure Grant.

The PF Charitable Trust Fund represents monies restricted to the Oxford Infrastructure Grant.

The Doris Field Charitable Trust represents monies restricted to the Oxford Infrastructure Grant.

The Edwards Cadbury Trust represents monies restricted to the Birmingham Infrastructure Grant.

The GJW Turner Charitable Trust represents monies restricted to the Birmingham Infrastructure Grant.

The Miss Margaret Butters Reekie Charitable Trust represents monies restricted to the ICONIC research programme.

Other funds represent monies restricted to Infrastructure grants.

Methotrexate prodrug

The Balcombe Trust Fund represents monies restricted to the PhD awarded by BCRT in 2018 seeking to develop a targeted methotrexate prodrug.

The Charity of Stella Symons represents monies restricted to the PhD awarded by BCRT in 2018 seeking to develop a targeted methotrexate prodrug

Other research

The Liz Clarke-Saul Fund represents monies restricted for research into adamantinoma.

Other funds represent monies restricted to research.

Non research

The Takeda Restricted Fund represents monies restricted to the BCRT annual patient conference

The My Blue Heart fund represents monies restricted to support.

The James Tudor Foundation fund represents monies restricted to a patient amputation resource

Other funds represent monies restricted to non-research charitable activities.

23. DESIGNATED FUNDS

	AT 1/1/21	PAID	DESIGNATED	AT 31/12/21
	£	£	£	£
Patient support grants	29,000	(29,000)		
Infrastructure grants	67,000	(67,000)	160,000	160,000
ICONIC Grant	175,000	(175,000)		
Information and awareness charitable activities	43,000	(43,000)	70,000	70,000
Early careers fellowship	-	-	500,000	500,000
Clinical Trial Support grants	-	-	150,000	150,000
Consortia and Research Meeting grants	-	-	240,000	240,000
Hamilton Programme of Osteosarcoma Research	-	-	125,000	125,000
Other grants	175,000	(175,000)	300,000	300,000
TOTAL FUNDS	489,000	(489,000)	1,545,000	1,545,000

Our patient support grants are available to help with the additional costs that a diagnosis of bone cancer and subsequent treatment can bring.

Infrastructure grants support tissue collection at treatment centres across the UK.

The ICONIC programme supports the collection of tissue samples from osteosarcoma patients, with the aim of improving future outcomes.

Information and awareness charitable activities support planned patient advocacy and the creation and distribution of targeted information resources.

Early career fellowship grants will ensure that future leaders in the field are able to create their own programme of research.

Our Clinical Trial Support Grants will provide additional support to ongoing clinical trials, ensuring no stone is left unturned and every opportunity is explored for maximum patient benefit.

In recognition of the need to bring the primary bone cancer research and clinical communities together, our new Consortia and Research Meeting Grants will bring about new levels of international collaboration and stimulate partnership working, accelerating progress.

Hamilton Programme of Osteosarcoma Research is aimed at supporting a programme of research, which will come together to make progress and improve outcomes for patients.

Other designated grant funds relate to unrestricted grant funding to support a range of projects throughout 2022.

24. RELATED PARTY DISCLOSURES


Trustees are required to disclose all relevant interests and register them with the Clerk to the Trustees and in accordance with the Charity's policy to withdraw from decisions where a conflict of interest arises.

Any individual with an interest in a matter being discussed at a meeting must declare the interest to the meeting. The chairman of the meeting will then decide whether that individual should withdraw during the discussion and, if not, whether the individual should be entitled to vote on the matter under discussion.

During the year ended 31st December 2021, consultancy services of £1,170 (2020: 1,620) were provided by Sarah B Dawson Limited, a company in which one of the trustees to the charity, Sarah B Dawson is also a director.

25. COMMITMENTS

As at 31 December 2021 the charity has committed to funding further research grants of £120,895. These commitments are subject to conditions and review within the control of the charity and accordingly not recognised as grant liabilities within notes 18 and 19.



©Bone Cancer Research Trust 2022
10 Feast Field,
Horsforth,
Leeds LS18 4TJ

bcrt.org.uk
0113 258 5934

[@BCRT](https://twitter.com/BCRT)
[f/BoneCancerResearchTrust](https://www.facebook.com/BoneCancerResearchTrust)
[@bonecancerresearch](https://www.instagram.com/bonecancerresearch)

Registered charity in England & Wales:
1159590

Also available
**THE BIGGEST EVER
COMMITMENT
TO PRIMARY
BONE CANCER.
OUR STRATEGY
2017 - 2022**

and
**LIVING WITH, AND
BEYOND, PRIMARY
BONE CANCER**

Please contact us to request your free
copy or visit our website for a printable
/ downloadable version.

